Loading...
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Despite initial complete remission rates of up to 90%, long-term, disease-free survival remains poor in patients with newly diagnosed acute lymphoblastic leukemia (ALL). Response to salvage chemotherapy is suboptimal; therefore, novel therapeutic agents are being investigated in order to improve out...
Na minha lista:
| Udgivet i: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Harborside Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6505665/ https://ncbi.nlm.nih.gov/pubmed/31186988 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|